The present invention provides ligands capable of binding to prion protein, such as anti-prion protein antibodies and antigen-binding fragment thereof, for the prevention and/or treatment of synucleinopathies, such as Parkinson's disease. The present invention also provides pharmaceutical compositions comprising such ligands and methods for treating synucleinopathies or for reducing the uptake of ±-synuclein fibrils.
Ligands binding to prion protein for use in the treatment of synucleinopathies / Legname, G.. - (2017 May 23).
Ligands binding to prion protein for use in the treatment of synucleinopathies
Legname, G.
2017-05-23
Abstract
The present invention provides ligands capable of binding to prion protein, such as anti-prion protein antibodies and antigen-binding fragment thereof, for the prevention and/or treatment of synucleinopathies, such as Parkinson's disease. The present invention also provides pharmaceutical compositions comprising such ligands and methods for treating synucleinopathies or for reducing the uptake of ±-synuclein fibrils.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
